CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
977.49MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.8640xvs all stocks
52-Week Change
59.61%vs all stocks
Market Capitalization
977.49MUSDvs all stocks (USD)
Enterprise Value
762.99MUSDvs all stocks (USD)
Forward P/E
-10.89xvs Biotechnology peers
Price to Book (MRQ)
4.34xvs Biotechnology peers
Enterprise to EBITDA
-13.42xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-21.66%vs Biotechnology peers
Return on Equity (TTM)
-35.43%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-56.85MUSDvs all stocks (USD)
Net Income (TTM)
-54.13MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-44.53MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-27.40MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-42.97MUSDvs all stocks (USD)
Pre-tax Income
-15.28MUSDFY2025 · Dec 31, 2025Net Income
-15.28MUSDFY2025 · Dec 31, 2025EBIT
-42.97MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-70.01MUSDFY2025 · Dec 31, 2025Research & Development
33.72MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
9.25MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.50MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-15.28MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-9.97MUSDFY2025 · Dec 31, 2025Free Cash Flow
-10.14MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
4.58MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-15.28MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
105.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
5.33MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
38.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-91.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-70.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-174.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-91.75MUSDFY2025 · Dec 31, 2025Sale of Investments
84.13MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-7.80MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
84.12MSharesUpdated Sep 27, 2026Float Shares
72.79MSharesUpdated Sep 27, 2026Shares Short
17.18MSharesUpdated Sep 27, 2026Short Ratio
21.53daysvs all stocks
Short % of Shares Outstanding
23.21%vs all stocks
% Held by Insiders
3.51%vs all stocks
% Held by Institutions
85.75%vs all stocks
Total Cash (MRQ)
215.23MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.56USDUpdated Sep 27, 2026Total Debt (MRQ)
728.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0032xvs Biotechnology peers
Current Ratio (MRQ)
16.16xvs Biotechnology peers
Book Value per Share (MRQ)
2.68USDUpdated Sep 27, 2026Total Assets
71.12MUSDvs all stocks (USD)
Total Current Assets
58.21MUSDFY2025 · Dec 31, 2025Total Liabilities
9.91MUSDFY2025 · Dec 31, 2025Total Non-current Assets
12.90MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
534.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.38MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
4.58MUSDFY2025 · Dec 31, 2025Other Short-term Investments
52.17MUSDFY2025 · Dec 31, 2025Accounts Receivable
37.00KUSDFY2025 · Dec 31, 2025Accounts Payable
2.49MUSDFY2025 · Dec 31, 2025Short-term Debt
403.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
238.00KUSDFY2025 · Dec 31, 2025Long-term Debt
534.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-412.29MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
61.20MUSDvs all stocks (USD)
52-Week Low
6.39USDUpdated Sep 27, 202652-Week High
26.95USDUpdated Sep 27, 202652-Week Change
59.61%vs all stocks
Beta
0.8640xvs all stocks
50-Day MA
13.77USDUpdated Sep 27, 2026200-Day MA
14.08USDUpdated Sep 27, 2026Avg 10-Day Volume
1.44MSharesUpdated Sep 27, 2026Avg 30-Day Volume
980.27KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-0.6400USDUpdated Sep 27, 2026Other Income / Expense
25.18MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 260
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.54
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Frontier Biotechnologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Procept BioRobotics Corporation
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Ausun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wuhan Huakang Century Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Highfine Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cisen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Edan Instruments Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Er-Kang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Northeast Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow